Phase 3 CARDIO-TTRansform Trial Results: New Insights into Eplontersen for ATTR Cardiomyopathy
The Phase 3 CARDIO-TTRansform trial of eplontersen in ATTR cardiomyopathy did not meet its primary endpoint of reducing cardiovascular mortality and recurrent cardiovascular events. The study demonstrated a favorable safety profile, with a prespecified monotherapy subgroup showing a nominally significant benefit. These results underscore both the progress made with current standard-of-care therapy and the ongoing […]